Recently, four heterocyclic compounds containing 1,2,4-triazole (designated as Y2, Y3, Y30, and Y32) were synthesized by our lab. Previous data showed that 1,2,4-triazole nucleus posses a wide range of pharmacological activities such as antioxidant, antiviral, antitumor and antibacterial activities. Currently, the need for triazole derivatives with a broad spectrum of antibacterial activity are in the rise. Therefore, these data encouraged us to test newly synthesized 1,2,4-triazole compounds for their antibacterial activity against three types of bacteria: standard, environmental and medical bacteria. Both well diffusion and broth dilution methods were employed to examine the potential antibacterial activity against the aforementioned types of bacteria. The standard bacteria include Staphylococcus aureus ATCC 29213, Staphylococcus epidermis ATCC 12228, and Bacillus
Introduction
1,2,4-Triazoles and their derivatives are important group of heterocyclic compounds characterized by a five-membered ring of two carbons and three nitrogen atoms. The biological activity of 1,2,4-triazoles and their derivatives have been demonstrated by various studies [1, 2] . For instance, data came from previous investigations showed that 1,2,4-triazole nucleus posses a wide range of pharmacological activities such as analgesic [3] , antibacterial [4] , antifungal [5] , anti-inflammatory [6] and antioxidant [1] properties. As a result of significant research on 1,2,4-triazoles, several formulations containing 1,2,4-triazole ring are now available in the pharmaceuticals market like triazolam and fluconazole [2] . Interest in the field of microbial chemotherapy is increasing due to several reasons, for instance, emergence and reemergence of new pathogens and the challenging problem of emerging resistances [2, 8, 9] . Therefore, there is a continuing need for new antimicrobial agents with more selectivity and lower side effect.
Apparently, 1,2,4-triazoles are currently attracting more interest in the field of microbial chemotherapy due to their broad spectrum of biological activities. Recently, four new 1,2,4-triazole derivatives ( Figure 1 ) were synthesized and identified, and their antioxidant activities were confirmed [1] . However, their antibacterial activities have never been tested. Thus, in this current study, we are interested in testing the antibacterial activity of these newly synthesized compounds against different types of bacteria, namely, standard, environmental, and medical bacterial strains. The latter group consists of newly isolated and identified bacteria from medical samples.
Antibacterial activity
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Figure 1: Chemical structure of the 1,2,4-triazole derivatives used in this study. 
Materials and Methods
Preparation of the New 1,2,4-Triazole Derivatives
The novel 1,2,4-triazole derivatives included in this study are assigned as compounds Y2, Y3, Y30, and Y32. The complete IUPAC name of these compounds are listed in Table 1 . These compounds were synthesized and characterized in a previous study by Al-Soud et al., 2010 [1] . Ten milligrams of each test compound were dissolved in 1 mL of dimethyl sulfoxide (DMSO) and used as test solution. DMSO and penicillin G (10 mg mL -1 ) were used as negative control and positive control, respectively. All test chemicals and controls were stored in dark at room temperature until use. Table 1 : Names and IUPAC nomenclature of the new 1,2,4-triazole derivatives tested in this study [1] .
Antibacterial activity testing
Bacterial strains
Bacterial strains used in this study are of three types: standard bacterial strains, environmental bacterial strains, and medical bacterial strains. The first type, i.e., the standard bacterial strains originate from the American type culture collection (ATCC). These strains include Staphylococcus aureus ATCC 29213,
Staphylococcus epidermis ATCC 12228, and Bacillus cereus ATCC11778. These strain were kindly offered by Dr. Emad Malkawi from the department of biological sciences at Yarmouk University, Jordan. The second type of bacteria includes Citrobacter sp., Bacillus pumilis, and Yersinia enterocolitica. Those bacterial strains were isolated and identified from the environment in previous studies in our research microbiology laboratory [10, 11] . In addition, three new bacterial strains (CS1, CS2, and CS3) were isolated and identified in this current study by the means of biochemical tests and the molecular methods. These bacteria compose the third type of bacteria, the medical bacterial strains.
Isolation and identification of new medical bacterial strains
Three newly isolated medical bacteria were included in this study. The new medical isolates originate from medical samples obtained from a local medical microbiology laboratory at local hospital in Al-Mafraq city, Jordan. These isolates (assigned as CS1, CS2, and CS3) were further cultivated and identified by both biochemical and molecular methods. All isolated bacteria were first Gram-stained and tested for oxidase [12] . After that, Gram-negative, oxidase-negative bacteria were identified by RapID ONE system and ERIC software (Remel, USA), whereas Gram-negative, oxidase-positive bacteria were identified by the 16S rDNA sequencing and analysis.
In the latter method, DNA was extracted from the isolate and subjected for 16S rDNA sequencing as previously described [10] . 16S rDNA sequencing was carried out by Macrogen sequencing facility (Macrogen Inc, Seoul, South Korea). The resulting nucleotide sequences were then analyzed by the Basic Local Alignment Search Tool (BLAST) search to identify the closest relatives of the strain.
Agar well diffusion and broth dilution methods
Antibacterial activity of the new 1,2,4-triazole compounds was evaluated by well diffusion method [13] as well as broth dilution method [12] . In the first method, Mueller-Hinton agar (MHA) medium was used to prepare MHA agar plates which were inoculated with the test bacterium. Then, six millimeter holes were punched in the MHA plates. After that, wells were filled with 50 μL of the test compounds (10 mg mL -1 ). Penicillin G (10 mg mL -1 ) was used as a positive control and DMSO was used as a negative control. After incubation, the average diameter of inhibition zone (IZ) around each well was measured to the nearest millimeter. Each experiment was done in triplicate. In respect to broth dilution method, mixtures of nutrient broth, inoculums, and test compounds were prepared in a microwell plates to yield the following final concentrations: 3000, 2000, 1000, 500, and 250 µg mL -1 . The MIC value is the lowest dilution of the test compound which inhibit the growth judged by lack of turbidity in the well.
Results
Isolation and identification of new medical bacterial strains
Three new bacterial strains were isolated, identified and used in this study. These isolates were assigned as CS1, CS2, and CS3. CS1 and CS2 were identified based on biochemical analysis as Escherichia coli and Shigella sonnei, respectively. Both strains are Gram negative and oxidase negative. The prominent biochemical properties of CS1 and CS2 are shown in Table 2 . On the other hand, strain CS3 was identified only after sequencing its 16S rDNA sequence. The 16S rDNA sequence of the newly isolated strains CS3 is depicted in Figure 2 . The strain is Gram-negative but oxidase-positive. The closest relatives of the isolated strains is Pseudomonas aeruginosa with 99% identity according to BLAST search. 
Antibacterial Activity
In this study, four triazole compounds (Y2, Y3, Y30, and Y32) were tested for their antibacterial activity against different types of bacteria. Two compounds (Y30 and Y32) didn't reveal any recognizable antibacterial activities under our experimental conditions. The other two compounds (Y2 and Y3) revealed variable degrees of antibacterial activity against certain bacterial strains. The antibacterial activities of the active compounds Y2 and Y3 are shown in Figure 3 
Discussion
Traizaoles are recognized as important antimicrobial group of synthetic heterocyclic compounds containing five-membered ring structure with three nitrogen atoms of two structural forms: 1,2,3-or 1,2,4-trazoles. 1,2,4-Triazoles may undergo substitution and modification by means of organic chemistry to yield a wide range of 1,2,4-triazole derivatives. Some substitutions may enhance the inhibitory effect of some 1,2,4-triazole compounds, while other substitutions may decrease the inhibitory effect of some 1,2,4-triazole compounds.
In this study, the antibacterial activity of the newly synthesized 1,2,4-triazole derivatives, was evaluated against three types of bacterial strains: standard, environmental, and medical bacterial strains. Diverse types of bacterial strains were included in this study to broaden the range of tested bacteria. In the current study, we isolated three new medical bacterial strains (CS1, CS2, and CS3) as representatives of pathogens transmitted between humans. Strain CS1 was found to represent a new strain of Escherichia coli which is associated with a range of diseases like gastroenteritis and urinary tract infections [14] . The second isolated strain is CS2 represents a new strain of Shigella sonnei, the etiologic agent of shigellosis, a global human health problem [15] . The third medical isolate is CS3,which represents a new strain of Pseudomonas aeruginosa which is an opportunistic bacterium that can cause serious infections in human [16] . The environment may also act as a source of bacterial pathogens, therefore, several environmental pathogenic and/or potentially pathogenic bacterial strains were also included in this study. The environmental strains include Citrobacter sp. which belongs to a genus consisting of several human pathogen [17] , Bacillus pumilis which was recently linked to cutaneous infections [18] , and finally, Yersinia enterocolitica, the causative agent of yersiniosis [19] .
Among the four tested compounds, Y2 and Y3 showed the highest antibacterial activity compared with the compounds with similar chemical structures such as Y30 and Y32. Moreover, among the most interesting findings in this study is the detection of medical strain of Pseudomonas aeruginosa that is resistant to the well known antibiotic penicillion G. This can be explained by either the emergence of new strains of this pathogen or the emergence of penicillin G-resistant mutant of the strain. Nevertheless, the strain was found to be sensitive to compound Y3, indicative of its ability to prevent the growth of several bacterial strains. In both cases, this encourages the continuous search for novel compounds assisting in the war against pathogens which are still the major causes of mortalities around the globe. The 1,2,4-triazole derivatives tested in this study share the same common nucleus structure and differ in the substituent groups and their positions (R 1 and R 2 , Figure 1 ). As shown in Figure 1 , the four 1,2,4-triazole derivatives contains methoxy group as R 1 group. Nevertheless, the position of methoxy group differs between the 1,2,4-triazole derivatives. The active compounds (Y2 and Y3) have 4-OMe whereas the inactive 1,2,4-triazole derivatives (Y30 and Y32) have 3-OMe. This may lead for the conclusion that the first position (4-OMe) has an enhancement effect, whereas the other position (3-OMe) has an attenuation effect. On the other hand, R
2 itself differs between the tested 1,2,4-triazole derivatives. The active compound Y2 contains an amino group whereas the active compound Y3 contains fluorine as R 2 substituent group. The presence of a amino group as R 2 substituent group in compound Y2 and fluorine atom as R 2 substituent group in compound Y3 appear to improve activity against some tested bacterial strains in comparison with compounds Y30 and Y32. Our results agree with some studies in the literature, especially those that have already shown that amino group(s) may enhance the antimicrobial activity of certain organic compounds [20] and those that shown that fluorine may enhance the antibacterial activity of organic compounds [21, 22] . It should be mentioned that R 2 in Y30 and Y32 is hydrogen and methoxy, respectively. Therefore, those types of the substituent group don't seem to have a positive effect towards enhancing the antibacterial activity of the tested derivatives.
Conclusion
The newly synthesized 1,2,4-triazole derivatives (Y2 and Y3) tested in this study posses a significant antibacterial activity against various types of bacteria. The compounds Y2 and Y3 were active against eight bacterial strains out of nine, indicative of their ability to inhibit the growth of several bacterial species. Interestingly, compound Y3 was found to have antibacterial activity higher than penicillin G (the positive control) against P. aeruginosa and similar to penicillin G against B. cereus, being the most active compounds. Interestingly, the amino group or fluorine as R 2 substituent group also appeared to have positive impact on antibacterial activity of these newly synthetic 1,2,4-triazole compounds. In addition, the enhanced antibacterial activity of Y2 and Y3 compounds could be due to the presence of methoxy group as R 1 group at position 4, instead of at position 3. Therefore, the antibacterial activity of Y2 and Y3 1,2,4-triazole compounds was attributed to the type and position of substituent groups.
